WNT/β-catenin signalling is activated in aldosteroneproducing adenomas and controls aldosterone production

Human Molecular Genetics

Volumn 23, Issue 4, 2014, Pages 889-905

  Berthon, Annabel ^a,b,c   Drelon, Coralie ^a,b,c   Ragazzon, Bruno ^d,e   Boulkroun, Sheerazed ^f,g   Tissier, Frédérique ^d,e,h,i   Amar, Laurence ^f,g,j   Samson Couterie, Benoît ^f,g   Zennaro, Maria Christina ^f,g,j   Plouin, Pierre François ^f,g,j   Skah, Seham ^b   Plateroti, Michelina ^b   Lefèbvre, Hervé ^k,l   Sahut Barnola, Isabelle ^a,b,c   Batisse Lignier, Marie ^a,b,c,m   Assié, Guillaume ^d,e,n   Martinez, Anne MarieLefrançois ^a,b,c   Bertherat, Jérôme ^d,e,n   Martinez, Antoine ^a,b,c   Val, Pierre ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CNRS   (France)

^c Faculté de Médecine   (France)

^d INSTITUT COCHIN   (France)

^e INSERM   (France)

^f PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ Institut Cochin   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k UNIVERSITÉ DE ROUEN   (France)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ Reference Center for Rare Epilepsies   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA CATENIN; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; SECRETED FRIZZLED RELATED PROTEIN 2; STEROID 21 MONOOXYGENASE; WNT PROTEIN;

ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; MOUSE; NONHUMAN; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY; ZONA GLOMERULOSA;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADULT; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERALDOSTERONISM; MALE; MEMBRANE PROTEINS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; WNT SIGNALING PATHWAY;

EID: 84892984544     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt484     Document Type: Article

References (65)

1. Plouin, P.-F., Amar, L. and Chatellier,G. (2004) Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol. Dial. Transplant., 19, 774-777.
2. Amar, L., Plouin, P.-F. and Steichen, O. (2010) Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J. Rare Dis., 5, 9.
3. Fagugli, R.M. and Taglioni, C. (2011) Changes in the perceived epidemiology of primary hyperaldosteronism. Int. J. Hypertens., 2011, 162804.
4. Steichen, O., Zinzindohoué, F., Plouin, P.-F. and Amar, L. (2012) Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm. Metab. Res., 44, 221-227.
5. Rossi, G.P.D. (2011) Diagnosis and treatment of primary aldosteronism. Rev. Endocr. Metab. Disord., 12, 27-36.
6. Jeunemaitre, X., Chatellier, G., Kreft-Jais, C., Charru, A., DeVries, C., Plouin, P.F., Corvol, P. and Menard, J. (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol., 60, 820-825.
7. Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C. and Plouin, P.-F. (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension, 56, 831-838.
8. Calhoun, D.A., White, W.B., Krum, H., Guo, W., Bermann, G., Trapani, A., Lefkowitz, M.P. and Ménard, J. (2011) Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo and active-controlled phase 2 trial. Circulation, 124, 1945-1955.
9. Heitzmann, D., Derand, R., Jungbauer, S., Bandulik, S., Sterner, C., Schweda, F., El Wakil, A., Lalli, E., Guy, N., Mengual, R. et al. (2008) Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J., 27, 179-187.
10. Davies, L.A., Hu, C., Guagliardo, N.A., Sen, N., Chen, X., Talley, E.M., Carey, R.M., Bayliss, D.A. and Barrett, P.Q. (2008) TASK channel deletion in mice causes primary hyperaldosteronism. Proc. Natl. Acad. Sci.USA, 105, 2203-2208.
11. Doi, M., Takahashi, Y., Komatsu, R., Yamazaki, F., Yamada, H., Haraguchi, S., Emoto, N., Okuno, Y., Tsujimoto, G., Kanematsu, A. et al. (2010) Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat. Med., 16, 67-74.
12. Oki, K., Plonczynski, M.W., Lam, M.L., Gomez-Sanchez, E.P. and Gomez-Sanchez, C.E. (2012) The potassium channel, Kir3.4 participates in Angiotensin II-stimulated aldosterone production by a human adrenocortical cell line. Endocrinology, 153, 4328-4335.
13. Monticone, S., Hattangady, N.G., Nishimoto, K., Mantero, F., Rubin, B., Cicala, M.V., Pezzani, R., Auchus, R.J., Ghayee, H.K., Shibata, H. et al. (2012) Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J. Clin. Endocrinol. Metab., 97, E1567-E1572.
14. Choi, M., Scholl, U.I., Yue, P., Björklund, P., Zhao, B., Nelson-Williams, C., Ji, W., Cho, Y., Patel, A., Men, C.J. et al. (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science, 331, 768-772.
15. Azizan, E.A.B., Lam, B.Y.H., Newhouse, S.J., Zhou, J., Kuc, R.E., Clarke, J., Happerfield, L., Marker, A., Hoffman, G.J. and Brown, M.J. (2012) Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa and zona fasciculata-like tumors. J. Clin. Endocrinol. Metab., 97, E819-E829.
16. Beuschlein, F., Boulkroun, S., Osswald, A., Wieland, T., Nielsen, H.N., Lichtenauer, U.D., Penton, D., Schack, V.R., Amar, L., Fischer, E. et al. (2013) Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat. Genet., 10.1038/ng.2550.
17. Boulkroun, S., Beuschlein, F., Rossi, G.-P., Golib-Dzib, J.-F., Fischer, E., Amar, L., Mulatero, P., Samson-Couterie, B., Hahner, S., Quinkler, M. et al. (2012) Prevalence, clinical, and molecular correlates of KCNJ5mutations in primary aldosteronism. Hypertension, 59, 592-598.
18. Åkerström, T., Crona, J., Delgado Verdugo, A., Starker, L.F., Cupisti, K., Willenberg, H.S., Knoefel, W.T., Saeger, W., Feller, A., Ip, J. et al. (2012) Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS ONE, 7, e41926.
19. Berthon, A., Sahut-Barnola, I., Lambert-Langlais, S., de Joussineau, C., Damon-Soubeyrand, C., Louiset, E., Taketo, M.M., Tissier, F., Bertherat, J., Lefrancois-Martinez, A.M. et al. (2010) Constitutive {beta}-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet., 19, 1561-1576.
20. Berthon, A., Martinez, A., Bertherat, J. and Val, P. (2011) Wnt/b-catenin signalling in adrenal physiology and tumour development. Mol. Cell. Endocrinol., 351, 87-95.
21. Boulkroun, S., Samson-Couterie, B., Golib-Dzib, J.-F., Amar, L., Plouin, P.-F., Sibony, M., Lefebvre, H., Louiset, E., Jeunemaitre, X., Meatchi, T. et al. (2011) Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology, 152, 4753-4763.
22. De Reynies, A., Assie, G., Rickman, D.S., Tissier, F., Groussin, L., Rene-Corail, F., Dousset, B., Bertagna, X., Clauser, E. and Bertherat, J. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol., 27, 1108-1115.
23. Suzuki, H., Watkins, D.N., Jair, K.W., Schuebel, K.E., Markowitz, S.D., Chen, W.D., Pretlow, T.P., Yang, B., Akiyama, Y., Van Engeland,M. et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet., 36, 417-422.
24. Morello, R., Bertin, T.K., Schlaubitz, S., Shaw, C.A., Kakuru, S., Munivez, E., Hermanns, P., Chen, Y., Zabel, B. and Lee, B. (2008) Brachy-syndactyly caused by loss of Sfrp2 function. J. Cell. Physiol., 217, 127-137.
25. Romero, D.G., Yanes, L.L., de Rodriguez, A.F., Plonczynski, M.W., Welsh, B.L., Reckelhoff, J.F., Gomez-Sanchez, E.P. and Gomez-Sanchez, C.E. (2007) Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretion. Endocrinology, 148, 2644-2652.
26. Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagnere, A.M., Rene-Corail, F., Jullian, E., Gicquel, C., Bertagna, X. et al. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res., 65, 7622-7627.
27. Lepourcelet, M., Chen, Y.N., France, D.S.,Wang,H., Crews, P., Petersen, F., Bruseo, C., Wood, A.W. and Shivdasani, R.A. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell, 5, 91-102.
28. Bassett, M.H., Suzuki, T., Sasano, H., White, P.C. and Rainey, W.E. (2004) The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Mol. Endocrinol., 18, 279-290.
29. Wu, H., Lin, Y., Li, W., Sun, Z., Gao, W., Zhang, H., Xie, L., Jiang, F., Qin, B., Yan, T. et al. (2011) Regulation of Nur77 expression by beta-catenin and its mitogenic effect in colon cancer cells. FASEB J., 25, 192-205.
30. Ragazzon, B., Libe, R., Gaujoux, S., Assie, G., Fratticci, A., Launay, P., Clauser, E., Bertagna, X., Tissier, F., de Reynies, A. et al. (2010) Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res., 70, 8276- 8281.
31. Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libe, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S. et al. (2011) beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin. Cancer Res., 17, 328-336.
32. Bonnet, S., Gaujoux, S., Launay, P., Baudry, C., Chokri, I., Ragazzon, B., Libe, R., Rene-Corail, F., Audebourg, A., Vacher-Lavenu, M.C. et al. (2011) Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and nonsecreting tumors. J. Clin. Endocrinol. Metab., 96, E419-E426.
33. Tadjine, M., Lampron, A., Ouadi, L., Horvath, A., Stratakis, C.A. and Bourdeau, I. (2008) Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease. Clin. Endocrinol. (Oxf.), 69, 367-373.
34. Li, Q., Ishikawa, T.-O., Oshima, M. and Taketo, M.M. (2005) The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis. Cancer Res., 65, 8622-8627.
35. Kielman, M.F., Rindapää, M., Gaspar, C., van Poppel, N., Breukel, C., van Leeuwen, S., Taketo, M.M., Roberts, S., Smits, R. and Fodde, R. (2002) Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat. Genet., 32, 594-605.
36. Albuquerque, C., Breukel, C., van der Luijt, R., Fidalgo, P., Lage, P., Slors, F.J.M., Leitao, C.N., Fodde, R. and Smits, R. (2002) The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum. Mol. Genet., 11, 1549-1560.
37. Buchert, M., Athineos, D., Abud, H.E., Burke, Z.D., Faux, M.C., Samuel, M.S., Jarnicki, A.G., Winbanks, C.E., Newton, I.P., Meniel, V.S. et al. (2010) Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet., 6, e1000816.
38. Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D.S., Moinard, C., Vasseur-Cognet, M., Kuo, C.J., Kahn, A., Perret, C. et al. (2006) Apc tumor suppressor gene is the 'zonation-keeper' of mouse liver. Dev. Cell, 10, 759-770.
39. Bovolenta, P., Esteve, P., Ruiz, J.M., Cisneros, E. and Lopez-Rios, J. (2008) Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J. Cell. Sci., 121, 737-746.
40. Nojima, M., Suzuki, H., Toyota, M., Watanabe, Y., Maruyama, R., Sasaki, S., Sasaki, Y., Mita, H., Nishikawa, N., Yamaguchi, K. et al. (2007) Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene, 26, 4699-4713.
41. Suzuki, H., Toyota, M., Carraway, H., Gabrielson, E., Ohmura, T., Fujikane, T., Nishikawa, N., Sogabe, Y., Nojima, M., Sonoda, T. et al. (2008) Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br. J. Cancer, 98, 1147-1156.
42. Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A.R., Li, Z., Croce, C.M., van Wijnen, A.J., Stein, J.L. et al. (2012) miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem., 287, 42084-42092.
43. Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G. and Delany, A.M. (2010) miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J. Biol. Chem., 285, 25221-25231.
44. Snyder, C.M., Rice, A.L., Estrella, N.L., Held, A., Kandarian, S.C. and Naya, F.J. (2013) MEF2A regulates the Gtl2-Dio3 microRNA mega-cluster to modulate WNT signaling in skeletal muscle regeneration. Development, 140, 31-42.
45. Fu, J., Tang, W., Du, P., Wang, G., Chen, W., Li, J., Zhu, Y., Gao, J. and Cui, L. (2012) Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst. Biol., 6, 68.
46. Kim, A.C., Reuter, A.L., Zubair, M., Else, T., Serecky, K., Bingham, N.C., Lavery, G.G., Parker, K.L. and Hammer, G.D. (2008) Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development, 135, 2593-2602.
47. Heikkila, M., Peltoketo, H., Leppaluoto, J., Ilves, M., Vuolteenaho, O. and Vainio, S. (2002) Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology, 143, 4358-4365.
48. Chen,M. and Hornsby, P.J. (2006) Adenovirus-deliveredDKK3/WNT4 and steroidogenesis in primary cultures of adrenocortical cells. Horm. Metab. Res., 38, 549-555.
49. Roy, L., McDonald, C.A., Jiang, C., Maroni, D., Zeleznik, A.J., Wyatt, T.A., Hou, X. and Davis, J.S. (2009) Convergence of 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A and glycogen synthase kinase-3beta/ beta-catenin signaling in corpus luteum progesterone synthesis. Endocrinology, 150, 5036-5045.
50. Parakh, T.N., Hernandez, J.A., Grammer, J.C., Weck, J., Hunzicker-Dunn, M., Zeleznik, A.J. and Nilson, J.H. (2006) Follicle-stimulating hormone/ cAMP regulation of aromatase gene expression requires beta-catenin. Proc. Natl. Acad. Sci. USA, 103, 12435-12440.
51. Boyer, A., Goff, A.K. and Boerboom, D. (2010) WNT signaling in ovarian follicle biology and tumorigenesis. Trends Endocrinol. Metab., 21, 25-32.
52. Boyer, A., Lapointe, E., Zheng, X., Cowan, R.G., Li, H., Quirk, S.M., DeMayo, F.J., Richards, J.S. and Boerboom, D. (2010)WNT4is required for normal ovarian follicle development and female fertility. FASEB J., 24, 3010-3025.
53. Hernandez Gifford, J.A., Hunzicker-Dunn, M.E. and Nilson, J.H. (2009) Conditional deletion of beta-catenin mediated by Amhr2cre in mice causes female infertility. Biol. Reprod., 80, 1282-1292.
54. Sun, Z., Cao, X., Jiang, M.-M., Qiu, Y., Zhou, H., Chen, L., Qin, B., Wu, H., Jiang, F., Chen, J. et al. (2012) Inhibition of b-catenin signaling by nongenomic action of orphan nuclear receptor Nur77. Oncogene, 31, 2653- 2667.
55. Rajalin, A.-M. and Aarnisalo, P. (2011) Cross-talk between NR4A orphan nuclear receptors and b-catenin signaling pathway in osteoblasts. Arch. Biochem. Biophys., 509, 44-51.
56. Lee, S.-O., Abdelrahim, M., Yoon, K., Chintharlapalli, S., Papineni, S., Kim, K., Wang, H. and Safe, S. (2010) Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res., 70, 6824-6836.
57. Kolluri, S.K., Bruey-Sedano, N., Cao, X., Lin, B., Lin, F., Han, Y.-H., Dawson, M.I. and Zhang, X. (2003) Mitogenic effect of orphan receptorTR3 and its regulation byMEKK1in lung cancer cells. Mol. Cell. Biol., 23, 8651- 8667.
58. Ke, N., Claassen, G., Yu, D.-H., Albers, A., Fan, W., Tan, P., Grifman, M., Hu, X., Defife, K., Nguy, V. et al. (2004) Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. Cancer Res., 64, 8208- 8212.
59. Shan, B.E., Wang, M.X. and Li, R.Q. (2009) Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest., 27, 604-612.
60. Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S. and Russo, G.L. (2012)The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol., 83, 6-15.
61. Romero, M., Jiménez, R., Hurtado, B., Moreno, J.M., Rodríguez-Gómez, I., López-Sepúlveda, R., Zarzuelo, A., Pérez-Vizcaino, F., Tamargo, J., Vargas, F. et al. (2010) Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur. J. Pharmacol., 627, 242-250.
62. Larson, A.J., Symons, J.D. and Jalili, T. (2012) Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv. Nutr., 3, 39-46.
63. Takahashi-Yanaga, F. and Kahn, M.(2010) TargetingWntsignaling: canwe safely eradicate cancer stem cells? Clin. Cancer Res., 16, 3153-3162.
64. Drelon, C., Berthon, A., Ragazzon, B., Tissier, F., Bandiera, R., Sahut-Barnola, I., De Joussineau, C., Batisse-Lignier,M., Lefrançois-Martinez, A.-M., Bertherat, J. et al. (2012) Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS ONE, 7, e44171.
65. Nelson, J.D., Denisenko, O. and Bomsztyk, K. (2006) Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat. Protoc., 1, 179-185.